Geneweldes
Latest round
- Series A
Last raised
- Jul 2025
Total raised
- Undisclosed
Investors
- 3
About Geneweldes
Ltd, trading as Geneweldes, is a biotechnology company focused on building a high-standard synthetic biology platform for pharmaceutical applications. The company collaborates with pharmaceutical and industrial partners to develop efficient synthetic pathways for active pharmaceutical ingredients. Geneweldes specializes in synthetic biology and recombinant protein expression, targeting high-value small molecule biologics including collagen, anti-aging proteins, anti-inflammatory proteins, and anti-oxidant peptides. The company has built a cell factory system for large-scale production and plans to launch two collagen-based functional products by 2025. Revenue is primarily generated from the commercial development and sale of small molecule recombinant protein products for medical, skincare, and health applications.
Who invested in Geneweldes
3 investors across 1 round
See all investors in Geneweldes
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
Jul 16, 2025
Amount
Undisclosed
Investors
Questions about Geneweldes
Who invested in Geneweldes?
Geneweldes has 3 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Geneweldes raised?
Geneweldes has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Geneweldes last raise money?
Geneweldes's most recent round on record is a Series A, in Jul 2025.
What does Geneweldes do?
Ltd, trading as Geneweldes, is a biotechnology company focused on building a high-standard synthetic biology platform for pharmaceutical applications.
Where is Geneweldes headquartered?
Geneweldes is headquartered in Hangzhou, China.
Which VCs invest in companies like Geneweldes?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back biotechnology companies at Geneweldes's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Geneweldes? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.